Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C -Mutant Non–Small Cell Lung Cancer

Rohit Thummalapalli; Ezra Bernstein; Benjamin Herzberg; Bob T. Li; Afsheen Iqbal; Isabel Preeshagul; Fernando C. Santini; Juliana Eng; Marc Ladanyi; Soo-Ryum Yang; Ronglai Shen; Piro Lito; Gregory J. Riely; Joshua K. Sabari; Kathryn C. Arbour

Journal ArticleOPEN ACCESS

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C -Mutant Non–Small Cell Lung Cancer

Thummalapalli R
Bernstein E
Herzberg B
et al.

JCO Precision Oncology (2023) (7)

DOI: 10.1200/po.23.00030

21Citations

12Readers

Abstract

Real-world analysis by @rohit_thum @RielyMD @KCArbourMD identifies KEAP1 mutations associated with resistance and recent anti–PD-(L)1 therapy exposure associated with toxicity among patients receiving sotorasib for advanced KRAS G12C+ NSCLC.

Cite

CITATION STYLE

APA

Thummalapalli, R., Bernstein, E., Herzberg, B., Li, B. T., Iqbal, A., Preeshagul, I., … Arbour, K. C. (2023). Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C -Mutant Non–Small Cell Lung Cancer. JCO Precision Oncology, (7). https://doi.org/10.1200/po.23.00030

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C -Mutant Non–Small Cell Lung Cancer

Abstract

Cite

Register to see more suggestions